HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.